Published On: Wed, Oct 19th, 2016

ImmunoGen, Inc. (NASDAQ:IMGN) Latest Broker Coverage


A number of investment brokers have recently updated their price targets on shares of ImmunoGen, Inc. (NASDAQ:IMGN).

Most recent broker ratings

08/05/2016 – ImmunoGen, Inc. had its “buy” rating reiterated by analysts at Jefferies. They now have a USD 6 price target on the stock.

05/19/2016 – ImmunoGen, Inc. had its “sector perform” rating reiterated by analysts at RBC Capital. They now have a USD 7 price target on the stock.

05/02/2016 – ImmunoGen, Inc. had its “market perform” rating reiterated by analysts at Leerink Swann. They now have a USD 8 price target on the stock.

05/02/2016 – ImmunoGen, Inc. had its “underweight” rating reiterated by analysts at Morgan Stanley. They now have a USD 5 price target on the stock.

02/01/2016 – ImmunoGen, Inc. had its “market perform” rating reiterated by analysts at Cowen. They now have a USD 8.5 price target on the stock.

11/10/2015 – ImmunoGen, Inc. had its “outperform” rating reiterated by analysts at Oppenheimer. They now have a USD 24 price target on the stock.

11/09/2015 – ImmunoGen, Inc. had its “buy” rating reiterated by analysts at Canaccord Genuity. They now have a USD 20 price target on the stock.

09/21/2015 – ImmunoGen, Inc. had its “hold” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 19 price target on the stock.

05/06/2015 – ImmunoGen, Inc. had its “neutral” rating reiterated by analysts at Credit Suisse. They now have a USD 10 price target on the stock.

05/03/2015 – ImmunoGen, Inc. was upgraded to “hold” by analysts at Zacks.

04/28/2015 – ImmunoGen, Inc. had its “outperform” rating reiterated by analysts at William Blair.

04/07/2015 – ImmunoGen, Inc. had its “neutral” rating reiterated by analysts at UBS. They now have a USD 9 price target on the stock.

12/22/2014 – ImmunoGen, Inc. had its “hold” rating reiterated by analysts at JP Morgan. They now have a USD 6 price target on the stock.

02/03/2014 – ImmunoGen, Inc. had its “neutral” rating reiterated by analysts at Guggenheim. They now have a USD 15 price target on the stock.

11/05/2013 – ImmunoGen, Inc. was downgraded to “sell” by analysts at Stifel Nicolaus.

The share price of ImmunoGen, Inc. (NASDAQ:IMGN) was down -0.43% during the last day of trading, with a day high of 2.39. 2177468 shares were traded during the last session.

The stock’s 50 day moving average is 2.69 and its 200 day moving average is 4.38. The stock’s market capitalization is 200.85M. ImmunoGen, Inc. has a 52-week low of 2.21 and a 52-week high of 14.22.

ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; IMGN529, and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra). Its FORWARD II consists of cohorts assessing Mirvetuximab soravtansine in combination with, in separate doublets, Avastin (bevacizumab), pegylated liposomal doxorubicin (PLD), and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4.